Twist’s massively parallel silicon-based DNA synthesis platform produces highly uniform and accurate oligos, with 90% of oligos represented within <2.5x of the mean, along with an industry-leading low error rate of 1:2,000 nt.
Combined with our well established molecular biology expertise, the Twist oligo synthesis platform enables the fabrication of highly diverse gene mutant libraries with excellent variant representation and highly specific user-defined composition with no unwanted bias or motifs. Twist library technology enables a comprehensive interrogation of the variant sequence space.
Twist Biopharma, a vertical within Twist Bioscience, has developed a Library of Libraries containing multiple pre-constructed and validated libraries against many high-value targets with which scientists can build a comprehensive and robust antibody discovery platform.
In this webinar, you'll learn
- How Twist Bioscience leverages DNA synthesis capability to provide unique advantages for lead antibody identification and optimization
- How precise amino acid ratio control in every position allows for targeted antibody optimization
- How Twist Biopharma’s innovative “Library of Libraries” creates new sequence space for therapeutic development, specifically for hard-to-drug targets
- How TAO (Twist Antibody Optimization) platform enables the generation of antibody sequences that are fully human and devoid of manufacturing liabilities